Drug news
Optimer Pharma agrees a licence to Cubist Pharma to market Dificid in USA
Optimer Pharma has agreed with Cubist Pharma for Cubist Pharma to market Dificid(fidaxomicin) in the USA for a two year period. The alliance is expected to help Optimer gain market share in the antibiotic space by using the experienced sales force from Cubist, which markets Cubicin (daptomycin for injection), a therapy for Staphylococcus aureus bacteremia, including right-sided endocarditis, and complicated skin infections caused by certain Gram-positive bacteria, including MRSA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.